Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Core One Labs
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 1 of pre-clinical development, clearly demonstrate that many of chosen bio-compounds have potential to exert beneficial effects that mitigate neurological deficits associated with many CNS disorders and mental health conditions.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 16, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Core One Labs
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : University of Barcelona
Deal Size : Undisclosed
Deal Type : Agreement
Details : The University of Barcelona, Faculty of Pharmacy and Food Sciences, Laboratory of Medicinal Chemistry, has been selected by Akome as the candidate, to provide technical guidance for the necessary in vitro studies of its proposed pharmaceutical psychedeli...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 25, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : University of Barcelona
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Akome is in process of identifying Contract Research Organizations (CROs) to work with as it sets the development process of its novel AKO001 psychedelic drug formulation and its advancement for the treatment of stroke.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 19, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Core One Labs
Deal Size : Undisclosed
Deal Type : Acquisition
Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech
Details : The acquisition of Akome further positions the Company at the forefront of development of psychedelic drugs for neurological diseases and mental disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 29, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Core One Labs
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Psilocybine,Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Core One Labs
Deal Size : Undisclosed
Deal Type : Acquisition
Core One Labs Completes Milestone Acquisition of Akome Biotech
Details : Currently Akome has 4 provisional matter of composition patents filed with the United States Patent and Trademark Office, one psilocybin-based, for addressing Alzheimer’s Disease; and one ketamine-based, for addressing depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 05, 2021
Lead Product(s) : Psilocybine,Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Core One Labs
Deal Size : Undisclosed
Deal Type : Acquisition